National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
Cervical Cancer Screening (PDQ®)
Patient VersionHealth Professional VersionLast Modified: 04/10/2008



Purpose of This PDQ Summary






Summary of Evidence






Significance






Evidence of Benefit






Accuracy of the Papanicolaou Test






New Screening Technologies






Screening Women Who Have Had a Hysterectomy






Screening Interval






HPV Testing






Screening Older Women






Evidence of Harm






Get More Information From NCI







Changes To This Summary (04/10/2008)






Questions or Comments About This Summary






More Information



Page Options
Print This Page  Print This Page
Print This Document  Print Entire Document
View Entire Document  View Entire Document
E-Mail This Document  E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
NCI Highlights
Report to Nation Finds Declines in Cancer Incidence, Death Rates

High Dose Chemotherapy Prolongs Survival for Leukemia

Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E

The Nation's Investment in Cancer Research FY 2009

Past Highlights
You CAN Quit Smoking Now!
Changes To This Summary (04/10/2008)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

HPV Testing

Added text about a randomized trial using both Pap and HPV testing in random order among women aged 30 to 69 years; sensitivity of HPV was higher than Pap testing, 95% and 55%, respectively (cited Mayrand et al. as reference 2).

Added text to state that among women older than 30 years, the Pap test had a 97% specificity compared with 94% for HPV DNA testing.

Added text about a randomized trial comparing screening HPV plus Pap test to Pap test on subsequent high risk cervical lesions or cancer that was conducted in Sweden among women aged 23 to 50 years (cited Naucler et al. as reference 3).

Back to TopBack to Top

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov